ENCALS Satellite Meeting 2020

Tuesday December 8th at 15.30-17.30 CET, ENCALS and TRICALS will be sharing…

Words Lucie van Leeuwen.Published December 6, 2020
ENCALS Satellite Meeting 2020

Tuesday December 8th at 15.30-17.30 CET, ENCALS and TRICALS will be sharing their latest updates in the online ‘ENCALS Satellite Meeting 2020’. This satellite meeting is prior to the 31st International Symposium on ALS/MND on 9-11 December 2020 (organised by the MND Association). The goal of this satellite meeting is to discuss international collaborations, SOPs and translation of new developments to the clinicWe will also briefly discuss various updates and research from TRICALS. 

The meeting will take place online. The programme of the meeting is as follows:

  • 15.30 – 15.50 ENCALS and TRICALS update
    Leonard van den Berg
  • 15.50 – 16.05 ENCALS Young Investigator Award 2020
    Ammar Al-Chalabi & Awardee
  • 16.05 – 16.20 TRICALS ICT Platform
    Orla Hardiman
  • 16.20 – 16.35 Disease aggressiveness and phases in imaging, electrophysiology
    and biomarkers: applications of the D50 model of ALS progression
    Julian Grosskreutz
  • 16.35 – 16.50 Arterial blood gas analysis is a proxy of VC in amyotrophic lateral sclerosis respiratory monitoring
    Adriano Chio
  • 16.50 – 17.15 Discussing the feasibility of clinical trials in patients with paediatric onset ALS
    Tessa Kliest
  • 17.15 – 17.25 EUpALS
    Evy Reviers
  • 17.25 – 17.30 Close of meeting

Attending this meeting is free of charge! However, you will need to fill in a registration form to receive a link to access the meeting. The registration form can be found here: https://www.encals.eu/meetings/encals-satellite-meeting-2020-virtual/

We look forward to seeing you there!

 


Share

Related news

Results of TUDCA-study: No effect of investigated compound
Results of TUDCA-study: No effect of investigated compound
The TUDCA-ALS consortium has announced the first findings of the TUDCA study, […]
Amylyx: no effect after analyzing phase 3 study
Amylyx: no effect after analyzing phase 3 study
The pharmaceutical company Amylyx announced the first results of the PHOENIX study. […]
Tofersen receives positive opinion from CHMP (EMA)
Tofersen receives positive opinion from CHMP (EMA)
The Committe of Medicinal Products for Human Use (CHMP) of the European […]
Results ADORE study: no effect of medication
Results ADORE study: no effect of medication
The pharmaceutical company Ferrer has announced their first results of the ADORE […]